Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. Issue 5 (31st May 2021)

• Record Type: Journal Article
• Authors: Orouji, Elias; Raman, Ayush T; Singh, Anand K; Sorokin, Alexey; Arslan, Emre; Ghosh, Archit K; Schulz, Jonathan; Terranova, Christopher; Jiang, Shan; Tang, Ming; Maitituoheti, Mayinuer; Callahan, Scot C; Barrodia, Praveen; Tomczak, Katarzyna; Jiang, Yingda; Jiang, Zhiqin; Davis, Jennifer S; Ghosh, Sukhen; Lee, Hey Min; Reyes-Uribe, Laura; Chang, Kyle; Liu, Yusha; Chen, Huiqin; Azhdarinia, Ali; Morris, Jeffrey; Vilar, Eduardo; Carmon, Kendra S; Kopetz, Scott E; Rai, Kunal
• Is Part Of: Gut. Volume 71:Issue 5(2022)
• Page Start: 938
• Page End: 949
• Publication Date: 2021-05-31
• Subjects: colorectal cancer -- cancer genetics -- colon carcinogenesis -- adenocarcinoma; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2020-322835
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: Enhancer aberrations are beginning to emerge as a key epigenetic feature of colorectal cancers (CRC), however, a comprehensive knowledge of chromatin state patterns in tumour progression, heterogeneity of these patterns and imparted therapeutic opportunities remain poorly described. Design: We performed comprehensive epigenomic characterisation by mapping 222 chromatin profiles from 69 samples (33 colorectal adenocarcinomas, 4 adenomas, 21 matched normal tissues and 11 colon cancer cell lines) for six histone modification marks: H3K4me3 for Pol II-bound and CpG-rich promoters, H3K4me1 for poised enhancers, H3K27ac for enhancers and transcriptionally active promoters, H3K79me2 for transcribed regions, H3K27me3 for polycomb repressed regions and H3K9me3 for heterochromatin. Results: We demonstrate that H3K27ac-marked active enhancer state could distinguish between different stages of CRC progression. By epigenomic editing, we present evidence that gains of tumour-specific enhancers for crucial oncogenes, such as ASCL2 and FZD10, was required for excessive proliferation. Consistently, combination of MEK plus bromodomain inhibition was found to have synergistic effects in CRC patient-derived xenograft models. Probing intertumour heterogeneity, we identified four distinct enhancer subtypes (EPIgenome-based Classification, EpiC), three of which correlate well with previously defined transcriptomic subtypes (consensus molecular subtypes, CMSs). Importantly, CMS2 can be divided into two EpiC subgroups with significant survival differences. Leveraging such correlation, we devised a combinatorial therapeutic strategy of enhancer-blocking bromodomain inhibitors with pathway-specific inhibitors (PARPi, EGFRi, TGFβi, mTORi and SRCi) for EpiC groups. Conclusion: Our data suggest that the dynamics of active enhancer underlies CRC progression and the patient-specific enhancer patterns can be leveraged for precision combination therapy.